Genetic architectures of the human hippocampus and those involved in neuropsychiatric traits.

Genetic architectures of the human hippocampus and those involved in neuropsychiatric traits.

Publication date: Oct 11, 2024

The hippocampus, with its complex subfields, is linked to numerous neuropsychiatric traits. While most research has focused on its global structure or a few specific subfields, a comprehensive analysis of hippocampal substructures and their genetic correlations across a wide range of neuropsychiatric traits remains underexplored. Given the hippocampus’s high heritability, considering hippocampal and subfield volumes (HASV) as endophenotypes for neuropsychiatric conditions is essential. We analyzed MRI-derived volumetric data of hippocampal and subfield structures from 41,525 UK Biobank participants. Genome-wide association studies (GWAS) on 24 HASV traits were conducted, followed by genetic correlation, overlap, and Mendelian randomization (MR) analyses with 10 common neuropsychiatric traits. Polygenic risk scores (PRS) based on HASV traits were also evaluated for predicting these traits. Our analysis identified 352 independent genetic variants surpassing a significance threshold of 2. 1 cD7 10 within the 24 HASV traits, located across 93 chromosomal regions. Notably, the regions 12q14. 3, 17q21. 31, 12q24. 22, 6q21, 9q33. 1, 6q25. 1, and 2q24. 2 were found to influence multiple HASVs. Gene set analysis revealed enrichment of neural differentiation and signaling pathways, as well as protein binding and degradation. Of 240 HASV-neuropsychiatric trait pairs, 75 demonstrated significant genetic correlations (P 

Open Access PDF

Concepts Keywords
Biobank Aged
Genetic Female
Global Genome-Wide Association Study
Neuropsychiatric Hippocampus
Hippocampus
Humans
Magnetic Resonance Imaging
Male
Mendelian Randomization Analysis
Mental Disorders
Middle Aged
Multifactorial Inheritance
Neuropsychiatric
Parkinson’s disease
Pleiotropic

Semantics

Type Source Name
disease MESH Polygenic risk scores
pathway REACTOME Reproduction
drug DRUGBANK Esomeprazole
disease MESH atrophy
drug DRUGBANK Carboxyamidotriazole
disease MESH bipolar disorder
disease MESH schizophrenia
disease MESH etiology
disease MESH lifestyle
drug DRUGBANK Ademetionine
disease MESH brain disorders
disease MESH attention deficit hyperactivity disorder
disease MESH anorexia nervosa
disease MESH anxiety
disease MESH epilepsy
disease MESH insomnia
disease MESH Parkinson’s disease
disease MESH post traumatic stress disorder
drug DRUGBANK L-Valine
drug DRUGBANK Coenzyme M
drug DRUGBANK Trestolone
pathway REACTOME Acetylation
pathway KEGG Hippo signaling pathway
pathway KEGG Wnt signaling pathway
disease MESH glioma
pathway KEGG Glioma
drug DRUGBANK Zinc
drug DRUGBANK Hyaluronic acid
disease MESH abnormalities
disease MESH pus
disease MESH psychiatric diseases
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH anxiety disorder
disease MESH Alzheimer’s disease
pathway REACTOME Apoptosis
drug DRUGBANK L-methionine (R)-S-oxide
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH Huntington’s disease
disease MESH mild cognitive impairment
disease MESH dementia
disease MESH dilated cardiomyopathy
pathway KEGG Dilated cardiomyopathy
drug DRUGBANK Troleandomycin
drug DRUGBANK Guanosine
disease MESH hemolysis
disease MESH panic disorder
disease MESH neuroticism
disease MESH depression
drug DRUGBANK Indoleacetic acid
disease MESH prostate cancer
pathway KEGG Prostate cancer
drug DRUGBANK Sulpiride
disease MESH childhood onset schizophrenia
drug DRUGBANK Selenium
disease MESH Parkinsonism
drug DRUGBANK Tretamine
disease MESH Cortical thinning

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *